The HAP1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted population designed for studying the intracellular trafficking adaptor HAP1. This polyclonal knockout product is derived from the HeLa cell line and carries a targeted disruption of the HAP1 gene, resulting in a loss-of-function model. The polyclonal format provides a heterogeneous cell pool, enabling robust phenotypic analysis without the bias of single-cell clonal selection. Researchers can utilize these cells to dissect HAP1-dependent processes in a well-characterized human epithelial background.
The host cell line, HeLa, is an immortalized epithelial cell line originally derived from a cervical adenocarcinoma of a patient (Henrietta Lacks) and is HPV18-positive. HeLa cells are widely employed in biomedical research due to their robust growth, ease of handling, and extensive characterization. Their epithelial origin makes them particularly suitable for investigating intracellular trafficking, membrane dynamics, and cancer-related pathways. The cervical adenocarcinoma background also provides a relevant context for studies linking autophagy and cell proliferation.
HAP1 functions as a critical adaptor protein linking huntingtin (HTT) to molecular motors such as dynein/dynactin and kinesin-1. It is activated downstream of BDNF/TrkB signaling and regulated by CREB, and interacts with multiple factors including huntingtin, dynactin p150Glued, kinesin-1, Rab11-FIP3, myosin VI, optineurin, and TRAK1. Through these interactions, HAP1 coordinates retrograde and anterograde vesicular transport along microtubules, directly impacting autophagy flux (LC3, p62) and endosomal recycling (Rab5, Rab11). Disruption of HAP1 is predicted to impair the trafficking of autophagosomes and endosomes, potentially altering growth factor receptor recycling and cellular homeostasis.
In the HeLa context, HAP1 knockout allows dissection of its role in autophagy and trafficking independent of neuronal-specific factors. While HAP1 is prominently studied in Huntington??s disease, its expression in cancer cells highlights functions beyond neurodegeneration. The loss of HAP1 may influence cell survival, proliferation, and response to metabolic stress through impaired autophagy and altered BDNF/TrkB signaling. This model thus serves as a versatile platform for both neurodegenerative disease research (e.g., huntingtin aggregation) and cancer biology, where autophagy modulation is therapeutically relevant.
These polyclonal knockout cells are suited for a range of assays, including western blotting to assess HAP1, LC3-I/II, and p62 levels; immunofluorescence colocalization of HAP1 with huntingtin or Rab11; autophagy flux measurements using bafilomycin A1; and co-immunoprecipitation of HAP1 with dynactin. They can be employed in high-content screening for huntingtin aggregation modulators or in live-cell imaging of vesicle motility. Researchers may also combine RT-qPCR for BDNF and TrkB expression with flow cytometry for apoptosis (annexin V) to evaluate downstream effects. For comprehensive technical support and additional product details, please contact Ascent Research.
